A collaboration that could be worth more than $300 million and bring over 200 advanced-manufacturing jobs to New Jersey is now underway. Celularity Inc. and MuseCell Innovations® Pte. Ltd. announced on August 27, 2026 a U.S. manufacturing collaboration for the Dezawa MuseCell® platform, under which Celularity will manufacture Dezawa MuseCells and MuseCell-derived products at its Florham Park, New Jersey facility using technology licensed from MuseCell Innovations, a Singapore-based company that holds the intellectual property behind the platform.
Founder, Chairman and CEO Robert J. Hariri, M.D., Ph.D., said: “Cellular medicine remains at the center of Celularity’s strategy, including our continued advancement of our proprietary placental-derived technologies. Our collaboration with MCI demonstrates how the manufacturing infrastructure and cellular expertise we have built can also support innovative third-party technologies. We look forward to expanding U.S. manufacturing for the Dezawa MuseCell platform and working with MCI to manufacture additional products derived from the platform.”
Inside the Florham Park Manufacturing Buildout
Under the collaboration, Celularity’s 147,215-square-foot, purpose-built Florham Park facility, which includes a cGMP-ready manufacturing center with nine Grade C/ISO 7 and six Grade D/ISO 8 suites, will produce Dezawa MuseCells (DMCs) as well as DMC-derived Dezawa MuseExosomes and Dezawa MuseSecretome. The platform combines qualified starting materials from perinatal, bone marrow, or adipose tissue with MCI’s proprietary Dezawa Method and its specifications for identity, purity, viability, potency, traceability, and lot release. MuseCell Innovations CEO and President Dominik Duscher, M.D., Ph.D., said: “Celularity brings the infrastructure and technical depth required to establish U.S. manufacturing across qualified bone marrow, adipose and perinatal sources. The central scientific and quality principle is that Dezawa MuseCell identity is defined by manufacture under the licensed Dezawa Method and conformance to MCI’s product specifications—not by the anatomical source alone. That distinction allows the platform to expand without abandoning the methodology and standards that define the DMC phenomenon.” Neither cenplacel-L, Celularity’s lead placental-derived cell therapy program, nor any MCI product described in the release has been approved or licensed by the FDA for any indication or use.
What the $300 Million Deal Is Actually Worth, and to Whom
MCI believes the expanded relationship could result in more than $300 million in aggregate purchases from Celularity over the next five years, contingent on successful manufacturing qualification and market demand, and the collaboration is anticipated to generate more than 200 high-tech employment opportunities in biomanufacturing, quality control, engineering, and support roles at the Florham Park site. New Jersey Governor Mikie Sherrill said: “By bringing a $300 million in business and more than 200 new jobs to New Jersey, Celularity and MuseCell Innovations are making it clear that our state is open for business. I first visited Celularity in 2022, and its trajectory from a homegrown startup here in New Jersey to a thriving public company is everything that drives my optimism about the potential of the New Jersey innovation economy. Advanced biomanufacturing continues to grow as a strong pillar of our economy, and investments like this are critical to driving job growth across our state. New Jersey is the medicine chest of the world, and my administration will keep working to make our government more accountable for businesses and position our state as the global leader in life sciences.”
